Abstract: The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-O and IFN? production, induce CD4? T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.

Abstract: Anti-TIGIT antibodies and antigen binding fragments thereof that inhibit TIGIT-mediated signalling are provided, together with combinations comprising said antibodies or antigen binding fragments thereof and methods for their use.

Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer and for enhancing immune function in an individual having cancer. The invention provides methods of treatment, methods for determining whether an individual suffering from a cancer is responding to treatment comprising a PD-1 axis binding antagonist, predicting responsiveness of an individual suffering from a cancer to treatment comprising a PD-1 axis binding antagonist, and methods of selecting a therapy for an individual suffering from cancer.

Abstract: Materials and methods for treating cancer, including materials and methods for treating cancer in patients identified as having elevated levels of Bim.

Abstract: The disclosure provides antibodies that specifically bind human MICA/B and methods of use thereof. In some aspects, the disclosure is directed to methods of treating a cancer in a subject, comprising administering to the subject an anti-MICA/B antibody.

Abstract: Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease, and rheumatoid arthritis. Rare occurrences of progressive multifocal leucoencephalopathy during treatment suggest the possibility that it may be related to natalizumab treatment. Monitoring for JCV and informing caregivers and patients about the manifestations of progressive multifocal leucoencephalopathy can improve the safety of natalizumab therapy.

Abstract: The present disclosure provides a pharmaceutical composition for preventing or treating a variety of diseases through c-Met activation in cells induced by the anti-c-Met antibody described herein which functions as a c-Met agonist. The current invention concerns a method for preventing or treating various diseases through c-Met activation by the anti-c-Met antibody described herein.

Abstract: The invention relates to agonistic anti-MET antibodies and uses thereof in the therapeutic treatment of disease. The antibodies bind with high affinity to the human and mouse hepatocyte growth factor (HGF) receptor, also known as MET, and are agonists of MET in both humans and mice, producing molecular and cellular effects resembling the effects of HGF binding.

Abstract: The present invention provides antibodies that bind to the IL-3 receptor alpha subunit alpha (Il3R?) chain, and compositions comprising such antibodies. The present invention provides methods for inhibiting or reducing an IL3R?-expressing cell population, the methods comprising contacting a population of IL3R?-expressing cells (e.g., cancer cells and/or cancer stem cells) with an antibody that binds to IL3R?. The present invention also provides antibody conjugates comprising an antibody that binds to an IL3R? chain linked to a cytotoxic agent or anticellular agent and compositions comprising such conjugates. The present invention also provides methods for preventing, treating and/or managing a disorder associated with IL3R?-expressing cells (e.g., a hematological cancer), the methods comprising administering to a subject in need thereof an antibody that binds to IL3R?.

Abstract: Antibodies and antigen binding fragments that specifically bind to IL-7R? are disclosed. Nucleic acids encoding the antibodies and antigen binding fragments, and vectors including the nucleic acid molecules are also provided. Methods for detecting a ca cancer or a cell that expresses IL-7R? using the antibodies and antigen binding fragments are disclosed, as is the use of the antibodies and antigen binding fragments to prevent and/or treat a subject with a cancer that expresses IL-7R?, such as acute lymphoblastic leukemia.

Abstract: The present invention relates to antigen binding molecules, including antibodies, fragments, and variants thereof, that bind to the TNF-related cytokine LIGHT (TNFSF14). The present invention also relates to methods of use of such antigen binding molecules in treating and/or preventing inflammatory disorders and immune disorders.

Abstract: The present invention relates to monospecific or bispecific antibody molecules that specifically bind the human DR5 antigen. The invention relates in particular to DR5-specific antibody molecules of the IgG1 isotype having a mutation in the Fc region that enhances clustering of IgG molecules after cell-surface antigen binding leading to the induction of DR5 signaling, apoptosis and cell death. The invention further relates to a combination of antibody molecules binding different epitopes on DR5. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer using these compositions.

Abstract: Antibodies are provided that alter the TLR4 signaling pathway to produce an immunosuppressive effect. The antibodies are useful for the treatment or prevention of an unwanted immune response in a subject, such as autoimmune disease, transplant rejection, and allergic reactions.

Abstract: The present invention provides an extracellular anti-linker/label epitope chimeric antigen receptor (anti-LLE CAR) comprising I) a linker/label epitope (LLE) binding domain, II) a transmembrane domain, and III) a signal transduction domain, wherein said extracellular LLE binding domain binds a target cell binding molecule (TCBM) comprising i) an antigen binding moiety (ABM), wherein said ABM binds specifically to an antigen expressed on a target cell, ii) a label moiety (LaM), wherein said LaM is a naturally occurring molecule in a subject or a derivative thereof, iii) a linker moiety (LiM) conjugating said ABM and said LaM, thereby forming a linker/label epitope (LLE), wherein said extracellular LLE binding domain binds said LLE with a higher preference than said naturally occurring molecule.

Abstract: Antibody drug conjugates against tissue factor. Also disclosed are pharmaceutical compositions comprising the antibodies and antibody drug conjugates, and therapeutic and diagnostic methods for using the antibodies and antibody drug conjugates.

Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Fucosyl-GM1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting Fucosyl-GM1, as well as methods for treating various diseases, including cancer, using anti-Fucosyl-GM1 antibodies.

Abstract: Disclosed are compositions and methods for targeted treatment of TAG-72-expressing cancers. In particular, affinity maturated single chain variable fragment (scFv) antibodies that bind TAG-72 on cancer cells are disclosed.

Abstract: The present invention generally relates to antigen-specific immunoconjugates for selectively delivering effector moieties that influence cellular activity. More specifically, the invention provides novel immunoconjugates comprising a first antigen binding moiety, an Fc domain and a single effector moiety. In addition, the present invention relates to polynucleotides encoding such immunoconjugates, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the immunoconjugates of the invention, and to methods of using these immunoconjugates in the treatment of disease.

Abstract: Various bispecific antibodies that specifically bind to both blood coagulation factor IX/activated blood coagulation factor IX and blood coagulation factor X and functionally substitute for the cofactor function of blood coagulation factor VIII, that is, the function to promote activation of blood coagulation factor X by activated blood coagulation factor IX, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor VIII were successfully discovered.

Abstract: Disclosed is an antibody which binds to olanzapine, which can be used to detect olanzapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of olanzapine, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.

Abstract: Provided are a thrombin antibody, an antigen-binding fragment and a pharmaceutical use thereof. Further provided are a chimeric antibody and a humanized antibody comprising a thrombin antibody CDR region, and a pharmaceutical composition comprising the thrombin antibody and the antigen-binding fragment thereof, as well as the use thereof as an anticoagulant drug. In particular, provided is a use of the humanized thrombin antibody in preparing a drug for treating a thrombin-mediated disease or condition.

Abstract: Provided are a combination of cross-linked hyaluronic acids comprising: a cross-linked hyaluronic acid having an elasticity of about 50 to about 200 Pa and a viscosity of about 20 to about 100 Pa, and a cross-linked hyaluronic acid having an elasticity of about 400 to about 800 Pa and a viscosity of about 40 to about 100 Pa, and a method for preparing the same.

Abstract: A process for the preparation of a diene elastomer modified by a 1,3-dipolar compound is provided. The process comprises a thermomechanical kneading of a mixture of a diene elastomer and of a 1,3-dipolar compound in an internal mixer in order to form a modified diene elastomer, followed by an extrusion of the modified diene elastomer.

Abstract: The present invention relates to a method of preparing a (meth)acrylonitrile-based polymer for preparing a carbon fiber, which comprises adding a reaction solution comprising a (meth)acrylonitrile-based monomer and a reaction solvent to a reactor to perform solution polymerization, performing solution polymerization under a condition in which a power consumption of the reactor is 1 to 5 kW/m3 when the reaction solution in the reactor has a viscosity of 0.1 poise or more and 250 poise or less, and performing solution polymerization under a condition in which a power consumption of the reactor is 8 to 13 kW/m3 when the reaction solution in the reactor has a viscosity of more than 250 poise and 450 poise or less.

Abstract: Provided herein is a cationic polymer obtainable by polymerization of at least one cationic monomer, at least one crosslinker and optionally further monomers, such as nonionic monomers, associative monomers, and/or chain transfer agents. The cationic polymer has an at least bimodal molecular weight distribution with at least one first peak (P1) and at least one second peak (P2), wherein the first peak has a rather low average sedimentation coefficient of ?10 Sved and the second peak has a rather high average sedimentation coefficient of ?10,000 Sved. The water-soluble polymer components of the cationic polymer are ?25% by weight related to the total amount of cationic polymer. Further provided herein is a process for obtaining such a cationic polymer as well as to an inverse dispersion, a thickener or a deposition aid, including at least one of such cationic polymers.

Abstract: This invention relates to a thioxanthone derivative photoinitiator, a radiation curable composition comprising the same and the use thereof. In particular, the invention relates to thioxanthone derivative photoinitiator suitable to be in one drop filling process for manufacturing liquid crystal display device without the concern of liquid crystal contamination.

Abstract: The present teachings are directed at 1,1-di substituted alkene monomers (e.g., methylene beta-ketoester monomers), methods for producing the same, polymerizable compositions including a methylene beta-ketoester monomer, and polymers, compositions and products formed therefrom. The monomer preferably is a high purity monomer. In the method for producing the methylene beta-ketoesters of the invention, a beta-ketoester may be reacted with a source of formaldehyde. The methylene beta-ketoester monomers may be used in monomer-based products (e.g., inks, adhesives, coatings, sealants or reactive molding) and polymer-based products (e.g., fibers, films, sheets, medical polymers, composite polymers and surfactants).

Abstract: Provided is a polymerizable compound usable in the preparation of an optical film, etc. having favorable reverse wavelength dispersibility.

Abstract: A system for precision polymerization is disclosed comprising at least one Michael-type monomer and a metal compound MR1R2R3 as sole catalyst and initiator, wherein M is aluminum, gallium or indium, each of R1, R2, and R3 independently is CI, F, I, Br, linear, branched or cyclic alkyl, heterocycloalkyl, linear, branched or cyclic alkenyl, heterocycloalkenyl, linear, branched, or cyclic alkenyl, linear, branched, or cyclic alkinyl, heterocycloalkinyl, linear, branched, or cyclic alkoxy, aryl, heteroaryl, aryloxy, silyl, metallocenyl, nitro, nitroso, hydroxy, or carboxyl, wherein each alkyl, alkenyl, alkinyl or alkoxy group independently has up to 12 carbon atoms, wherein each aryl or heteroaryl independently has 5 to 14 ring atoms, wherein any hetero group has at least one hetero atom selected from the group consisting of O, S, and N, wherein each alkyl, alkenyl, alkinyl or alkoxy, heterocycloalkyl, heterocycloalkenyl, heterocycloalkinyl, aryl, heteroaryl, aryloxy group can be substituted by 1 up to the highes

Abstract: The invention relates to polybutadiene, which contains the monomer units derived from 1,3-butadiene having a vinyl double bond in a proportion of 25 to 75 mole percent, having a trans-double bond in a proportion of 0 to 10 mole percent and a cis-double bond in a proportion of 25 to 75 mole percent, wherein the totality of the monomer units (A), (B) and (C) is supplemented to 100 mole percent, and which is characterized in that it has a number-average mole mass of 1,000 to 3,000 g/mole. The invention further relates to a method for producing polybutadienes, the use of the polybutadiene according to the invention and compositions containing polybutadiene according to the invention.

Abstract: To provide an electric wire and coil covered with a cured product of a heat- or photo-curable fluorinated polymer and having high insulating properties and high productivity. An electric wire comprising a conductor wire and a covering layer covering the outer periphery of the conductor wire, wherein the covering layer is made of a cured product of a curable composition comprising a fluorinated polymer containing at least three functional groups represented by the following formula (F): —Rf1COZ1??(F) (in the formula (F), Rf1 is a single bond, a fluoroalkylene group, or a fluoroalkylene group with at least two carbon atoms having an etheric oxygen atom between carbon-carbon atoms, Z1 is NR1NR2H, NR3OR4 or OR5, and R1, R2, R3, R4 and R5 are each independently a hydrogen atom or an alkyl group.

Abstract: The present invention relates to a method for making a direct emulsion of a copolymer in water, characterized in that it comprises the polymerization of at least, expressed as a percentage by weight of each of the monomers based upon the total weight of the monomers: a) 10 to 80% by weight of methacrylic acid and, optionally, of acrylic acid; b) 15 to 80% by weight of at least one non-ionic vinyl monomer; c) 0.05 to 9.5% by weight of 2-acrylamido-2-methylpropane sulfonic acid or a salt thereof; d) 0.5 to 30% by weight of at least one monomer containing at least one hydrophobic group; and e) 0.01 to 5% by weight of at least one crosslinking monomer; said polymerization being carried out in the presence of at least one surfactant. It also relates to the corresponding new copolymer emulsion in water, a method for thickening an aqueous composition comprising such an emulsion of copolymer and to an aqueous composition comprising such a copolymer emulsion.

Abstract: Power transmission belts have a hydrogenated nitrile-butadiene-PEG acrylate copolymer of 25% to 38% by weight by weight of at least one ?,?-ethylenically unsaturated nitrile unit, 40% to 60% by weight by weight of at least one conjugated diene unit and 10% to 25% by weight by weight of at least one PEG acrylate unit derived from a PEG acrylate of the general formula (I) where R is hydrogen or branched or unbranched C1-C20-alkyl, preferably methyl, ethyl, butyl or ethylhexyl, n is 1 to 8, preferably 2 to 8, more preferably 2 to 5 and most preferably 3 and R1 is hydrogen or CH3-, where the hydrogenated nitrile-butadiene-PEG acrylate copolymer, if n is 1, does not contain any further copolymerizable monomer unit having a free carboxylic acid group.

Abstract: The present invention provides a copolymer of 1,3,7-octatriene and isoprene having a narrow molecular weight distribution (Mw/Mn) and a hydride thereof. Furthermore, in a production method of a copolymer containing a structural unit derived from 1,3,7-octatriene and a structural unit derived from isoprene, high raw material conversions are achieved for a short polymerization time. Specifically, the copolymer is a copolymer containing a structural unit derived from 1,3,7-octatriene and a structural unit derived from isoprene and is a copolymer having a molecular weight distribution (Mw/Mn) of less than 1.44, or the like.

Abstract: Provided are methods for surface-modifying a rubber vulcanizate and surface-modified elastic bodies, which can cost-effectively provide a variety of functions, including sliding properties, liquid leakage resistance, and protein adsorption resistance. Included is a method for surface-modifying a rubber vulcanizate as a modification target, the method including: step 1 of forming polymerization initiation points A on the surface of the modification target; step 2 of radically polymerizing a monomer starting from the polymerization initiation points A to grow polymer chains; and step 3 of adding a silane compound to the surfaces of the polymer chains, followed by reaction with at least a fluoroalkyl group-containing silane compound to form modified polymer chains.

Abstract: An object of the present invention is to provide very versatile unsaturated polyester resin compositions. According to the present invention it has been found that very versatile resin compositions can be obtained using unsaturated polyester resin compositions each containing an unsaturated polyester resin and an aliphatic multifunctional allyl ester represented by the following formula (1): Z—(—COOCH2—CH?CH2)n ??(1) wherein n is an integer of 2 to 4; Z is an n-valent aliphatic hydrocarbon group, provided that Z is a bond only when n is 2.

Abstract: Described are silicone hydrogels with high levels of polyamides exhibiting an excellent balance of physical, mechanical, and biological properties. The silicone hydrogels are formed from a reactive monomer mixture comprising: a hydroxylalkyl (meth)acrylate monomer; hydroxyl-containing silicone components; and a polyamide, wherein the polyamide is present in an amount greater than 15 weight percent, based on the total weight of reactive components in the reactive monomer mixture.

Abstract: There is described an acrylic polyester resin, obtainable by grafting an acrylic polymer with a polyester material. The polyester material is obtainable by polymerizing (i) a polyacid component, with (ii) a polyol component, including—2,2,4,4-tetraalkyl-cyclobutane-1,3-diol. One of the polyacid component or the polyol component comprises a functional monomer operable to impart functionality on to the polyester resin, such that an acrylic polymer may be grafted with the polyester material via the use of said functionality. Also provided is an aqueous coating composition comprising the acrylic polyester resin and a metal packaging containing coated with the composition.

Abstract: The present invention relates to a method for producing a prepolymer that contains carbon-carbon multiple bonds, a polyol component A) being reacted with component B) that contains isocyanate groups and the polyol component comprising a polyether carbonate polyol that contains carbon-carbon multiple bonds.

Abstract: The invention provides polyurethane and polyisocyanurate foams and methods for the preparation thereof. More particularly, the invention relates to open-celled, polyurethane and polyisocyanurate foams and methods for their preparation. The foams are characterized by a fine uniform cell structure and little or no foam collapse. The foams are produced with a polyol premix composition which comprises a combination of a hydrohaloolefin blowing agent, a polyol, a silicone surfactant, and a sterically hindered amine catalyst.

Abstract: The present invention refers to a polymer blend comprising (i) between 10 wt % and 99.9 wt %, with respect to the total weight of the blend, of a thermoplastic host polymer, provided it is not a polyborosiloxane; and (ii) between 0.1 wt % and 90 wt %, with respect to the total weight of the blend, of a disulfide-containing self-healing polymer comprising a first polymeric chain fragment comprising one or more disulfide moieties and at least one moiety selected from the group consisting of —N(R1)—C(?O)—N(R2)—, —N(R1)—C(?O)—O— and —N(R1)—C(?O)—S—, wherein each R1 and R2 is independently selected from the group consisting of hydrogen, C1-C24-alkyl and C6-C15-aryl. The invention also refers to use of said blends, for example as cable sheaths.

Abstract: The present disclosure provides a preparation method of a shape memory polyurethane, which comprising: reacting 1,3,5,7-tetrahydroxyadamantane, ?-caprolactone, a catalyst and a solvent for 20-50 hours under the conditions of inert gas and 70° C. to 130° C. to obtain adamantyl star poly(?-caprolactone), wherein the mole ratio of the 1,3,5,7-tetrahydroxyadamantane to the ?-caprolactone is 1:(40-240); mixing the adamantyl star poly(?-caprolactone) with long-chain diol and diisocyanate, adding the catalyst and the solvent, and reacting for 3-9 hours at 50-100° C. to obtain an isocyanate-terminated polyurethane prepolymer, wherein the mass ratio of the adamantyl star poly(?-caprolactone) to the long-chain diol is 9:1-1:9; and adding a linking agent in the polyurethane prepolymer so that the linking agent reacts with isocyanate in the polyurethane prepolymer to obtain an adamantyl cross-linked shape memory polyurethane.

Abstract: Provided is a polycarbonate polyol used as a raw material of a polyurethane that has an excellent balance of flexibility, mechanical strength and solvent resistance. The polycarbonate polyol includes structural units derived from a polyhydric alcohol and has a hydroxyl value of 20 to 450 mg KOH/g. The polyhydric alcohol includes: a diol (A) containing not less than 70% by weight of a specific oxyalkylene glycol (A1); and a trihydric to hexahydric branched alcohol (B) having 3 to 12 carbon atoms. In the polycarbonate polyol, structural units derived from the branched alcohol (B) is contained in an amount of 0.005 to 5.0% by mole in the structural units derived from the polyhydric alcohol. A ratio of a structural unit (X1) represented by the following Formula (X1) in the structural units derived from the branched alcohol (B) is not higher than 50% by mole.

Abstract: Described herein is a cast elastomer including graphene nano platelets and a process for preparing the same.

Abstract: The blocked isocyanate is a blocked isocyanate containing a latent isocyanate group, which is an isocyanate group blocked with a blocking agent, wherein the blocked isocyanate includes a first latent isocyanate group that is an isocyanate group blocked with a first blocking agent and a second latent isocyanate group that is an isocyanate group blocked with a second blocking agent; and the first blocking agent is represented by general formula (1) below, and has a higher catalysis activity that activates the isocyanate group than that of the second blocking agent. (where R1 to R3 represent a hydrocarbon group having 1 to 12 carbon atoms or a hydrogen atom, and at least one of R1 to R3 represents a hydrogen atom, and R1 and R3 may be bonded to each other to form a heterocycle.

Abstract: The present disclosure provides a fire retardant composition that includes a non-intumescent composition and an intumescent composition, fire retardant coatings including the same, and methods of preparation and use thereof.

Abstract: The present disclosure relates to methods for preparing materials from heavy feedstocks. In particular, the disclosure provides a chemical process to convert heavy feedstocks with predominant polyaromatic hydrocarbon molecules or species, including the residues of petrochemical refining or extraction, into thermoset or thermoplastic materials that can be used alone or as a component in a composite material.

Abstract: A novel method for the preparation of biodegradable polymers is disclosed. The method produces polymers of high molecular weight and particularly allows for stirring throughout the polymerization reaction.

Abstract: A process for the production of a thermoplastic elastomer containing hard segments (a) of a polyester and soft segments (b) containing repeating units derived from an aliphatic carbonate, in which process a precursor thermoplastic elastomer is subjected to solid state post condensation at a temperature between 140 and 170° C. Also claimed is the thermoplastic elastomer.

Abstract: A polyether carbonate polyol with a nominal functionality of 3 or more includes an equivalent molecular weight between 20,000 and 500,000 Da, and content of between 0.5 wt % and 35 wt % of CO2 based on the total weight of the polyether carbonate polyol. The polyether carbonate polyol has adhesive and impact modifying properties.